Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
ANN ARBOR, Mich., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, has begun patient enrollment in the REVIVE Phase 3 clinical trial to
ANN ARBOR, Mich., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
Results Presented Today at the American Heart Association Scientific Sessions Show Ixmyelocel-T Met Primary Safety and Efficacy Endpoints in CLI Patients With No Revascularization Options
ANN ARBOR, Mich., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, will hold a Research and Development Day for investors on November
ANN ARBOR, Mich., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported financial results for the quarter and nine months ended
Researchers to Review Recent Preclinical and Clinical Findings on Use of Cellular Therapies Derived From Bone Marrow Stem Cells to Treat Chronic Cardiovascular Disease
ANN ARBOR, Mich., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced that final 12-month results from the RESTORE-CLI Phase 2b
ANN ARBOR, Mich., Oct. 31, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences,
ANN ARBOR, Mich., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Brian Gibson has been named vice president of
ANN ARBOR, Mich., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has been granted a key composition of matter
